Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Thorac Oncol. 2020 Feb 15;15(5):777–791. doi: 10.1016/j.jtho.2020.01.009

Figure 1. STING pathway proteins expression is associated with immune activation in lung adenocarcinoma.

Figure 1.

(A) Heatmap shows correlation of phospho-STING (Ser_366) protein levels with CGAS and other immune related proteins in the MD Anderson PROSPECT cohort, including treatment naïve adenocarcinoma (n=120, Spearman’s rho > 0.3, p<0.001).

(B) Expression of the STING downstream chemokine CXCL10 is correlated with the other STING related genes CCL5 and CGAS (p<0.001), with expression of selected targetable immune genes: CD274 (PD-L1), LAG3, CTLA4, IDO1, HAVCR2 and ICOS (Spearman’s rho > 0.5, p<0.001) and with CD8 mRNA levels, indicative of immune infiltration in PROSPECT LUAD cohort (n=120). (C-D) Individual dot-plots showing correlation of CXCL10 (C) and CCL5 (D) gene expression with selected targetable genes CD274 and CTLA4, and CD8 in PROSPECT LUAD cohort (n=120). (E) Correlation of CXCL10 with CCL5 and CGAS gene expression, with selected targetable immune genes and other immune markers from the list of Chen et al. in the treatment-refractory and relapsed BATTLE-2 cohort (n=95, Spearman’s rho > 0.3, p<0.001). (F-G) Individual dot-plots showing correlation of CXCL10 (F) and CCL5 (G) gene expression with selected targetable genes CD274 and CTLA4, and CD8 in BATTLE-2 cohort.